Board and leadership team

Our Board members are committed to a clear, strategic vision for the Group.
  • Audit
  • Nomination
  • Remuneration
  • Executive
  • Board

Bruno Angelici

Non-Executive Chairman

Appointment to the Board

Bruno Angelici was appointed to the Vectura Board on 1 December 2013 and became Non-Executive Chairman in February 2014. Following the merger with Skyepharma in June 2016, Bruno became Chairman of the enlarged Vectura Group plc.

Experience and expertise

Bruno has an MBA (Kellogg School of Management) and business and law degrees from Reims.
Bruno’s career includes senior management roles in pharmaceutical and medical device companies. Bruno retired from AstraZeneca in 2010 as executive vice president international after a 20-year career. He was responsible for Europe, Japan, Asia Pacific, Latin America, the Middle East and Africa, having originally joined as president of ICI Pharmaceuticals France. Prior to this, he was at Baxter, a US-based global supplier of medical devices. He has extensive international business leadership experience, including in the US, and brings a deep understanding to the Company of the medical device and pharmaceutical industries. Bruno was a member of the supervisory board of Wolters Kluwer NV, a global information services and publishing company, and also a non-executive director of Novo Nordisk A/S, a global healthcare company and world leader in diabetes care.

Current external appointments

Bruno is a non-executive director of Smiths Group plc.

Will Downie

Chief Executive Officer

Appointment

Will Downie was appointed Chief Executive Officer of Vectura in November 2019.

Experience and Expertise

Will holds a BSc (Hons) in Biochemistry from the University of Edinburgh.

Prior to joining Vectura, Will spent ten years as the Senior Vice President, Global Sales and Marketing at Catalent Inc. In this role, Will led the commercial effort and had responsibility for global sales, marketing and commercial operations activities. During his tenure, he developed an outstanding track record in helping drive the long-term growth of the company, as well as positioning Catalent as one of the leading brands in the pharmaceutical services space.

He has a deep understanding of the development and advanced drug delivery market, and has amassed significant experience in driving sustained long-term results, as well as building performance-focused organisations and meeting customer needs on a global scale.

Prior to Catalent, Will held positions as Vice President & General Manager, Global Molecular Imaging at GE Healthcare, Vice President Sales EMEA at Amersham Health and Director of Business Development and Commercial Operations at Quintiles Innovex UK Limited. In his early career, he worked in a range of sales and marketing management positions at both Sanofi and Merck & Co.

Current external appointments

Will does not currently hold any other directorships.

Paul Fry

Chief Financial Officer

Appointment to the Board

Paul Fry was appointed Chief Financial Officer of Vectura in October 2018.

Experience and Expertise

Paul graduated from Oxford University in 1988 and qualified as an accountant with the Chartered Institute of Management Accountants in 1991. He has significant experience in senior positions in the healthcare and telecommunications sectors.

Paul joined Vectura from Immunocore, the privately held leading T Cell Receptor biotechnology company, where he had been Chief Financial Officer since January 2017. Before joining Immunocore, he served as Director of Global Finance Operations at Vodafone Plc, where he was responsible for key financial controller activities and core processes as well as large transformation programmes.

Prior to his role at Vodafone, Paul spent more than 25 years at GlaxoSmithKline (GSK), where he held a number of senior roles including Head of Global Finance Services and as CFO for GSK’s Italian Pharmaceutical business.

Current external appointments

Paul is a Non Executive Director and chairman of the Audit Committee of Avacta Group plc, an AIM listed company.

Per-Olof Andersson

Non-Executive Director

Appointment to the Board

Dr Per-Olof Andersson joined the Vectura Board in April 2015.

Experience and expertise

He holds a degree in medicine from Lund University, Sweden.

Per-Olof is an expert in international research and development within the pharmaceuticals, biopharmaceuticals and speciality pharmaceutical industry and has considerable experience in respiratory therapeutic development. In 2011, Per-Olof retired from Almirall, where he was executive director for R&D and a member of the board of directors. Prior to joining Almirall in 2006, Per-Olof had a distinguished international career at Pharmacia and Pfizer over a period of nearly 20 years. Since 2011, Per-Olof has been an independent consultant advising biotech and pharma companies.

Current external appointments

Per-Olof does not currently hold any other directorships.

Neil Warner

Non-Executive Director

Appointment to the Board

Neil Warner was appointed to the Board of Vectura as a Non‑Executive Director in February 2011.

Experience and expertise

Neil holds an economics degree from the University of Leeds and is a Fellow of the Institute of Chartered Accountants.

Neil brings significant financial and leadership experience in multinational listed companies. He was finance director at Chloride Group plc, a position he held for 14 years until the company’s acquisition by Emerson Electric. Prior to this, Neil spent six years at Exel plc (formerly Ocean Group plc and acquired by DHL/Deutsche Post in December 2005), where he held a number of senior posts in financial planning, treasury and control. He has also held senior positions in Balfour Beatty plc (formerly BICC Group plc), Alcoa and PricewaterhouseCoopers and was a non-executive director of Dechra Pharmaceuticals plc, where he was the senior independent director and chair of the audit committee. Neil was formerly the non-executive chairman of Enteq Upstream plc, a specialist reach and recovery products and technologies provider to the upstream oil and gas services market.

Current external appointments

Neil is senior independent director and audit committee chair of Trifast plc, a global leader in design, technology and manufacturing of industrial fasteners for the automotive and technology sectors. He is also a non-executive director, chair of the audit committee and member of the remuneration committee of Directa Plus plc, which floated on AIM in May 2016. Directa Plus is one of the world’s largest producers of graphene-based materials – marketed under its “Graphene Plus” (G+) brand, which can be used by third parties in a wide variety of industrial and commercial applications.

Thomas Werner

Senior Independent Non-Executive Director

Appointment to the Board

Thomas Werner was appointed to the Board of Skyepharma as a non-executive director in May 2009 and joined the Board of Vectura following the merger in June 2016.

Experience and expertise

He holds a degree in chemistry from the University of Göttingen.

Thomas Werner has over 30 years of experience in the pharmaceutical industry, previously as senior vice president of GlaxoSmithKline, where he was managing director for Germany and also co-ordinated its European oncology business. Prior to that, he was responsible for Glaxo Wellcome Germany and Central Europe, Bristol-Myers Squibb Germany and ConvaTec Germany/Central Europe. He has held various non-executive positions including Riemser Pharma GmbH and New Oncology AG. Beside his business responsibilities he has previously served for many years on the board of trustees of the Paul Ehrlich Foundation and the Robert Koch Foundation and was a director of the American Chamber of Commerce in Germany representing healthcare companies. He stood down as a director of BSN Medical following the sale of the company in 2017.

Current external appointments

Thomas is chairman of the investment advisory committee of the Seventure (France) Health for Life capital investment fund. He is also vice chairman of Basilea Pharmaceutica Ltd.

Juliet Thompson

Non-Executive Director

Appointment to the Board

Juliet Thompson was appointed to the Vectura Board as a Non-Executive Director in December 2017.

Experience and expertise

Juliet has a BSc in economics and is a chartered accountant.

She has spent over 20 years actively involved in the life sciences sector working as an investment banker and strategic advisor to healthcare companies in Europe. She headed up the European healthcare team at Stifel (formerly Oriel) and prior to this was a founding partner of Code Securities, a healthcare investment banking boutique which was acquired by Nomura, later forming Nomura Code. Juliet stepped down as non-executive chairman and director of the Board of Premier Veterinary Group plc in 2018.

Current external appointments

Juliet sits on the boards of Novacyt S.A., a French diagnostic company whose shares are admitted to trade on AIM and Euronext, and GI Dynamics, Inc., a US headquartered, Australian stock exchange listed company. She chairs the audit committee of both of these companies. Juliet is also a trustee of Leadership through Sport & Business, a social mobility focussed charity.

Anne Whitaker

Non-Executive Director

Appointment to the Board

Anne Whitaker joined the Vectura Board in June 2018.

Experience and expertise

Anne has more than 25 years of experience in the life science industry, including senior leadership roles with large pharmaceutical, biotech, and speciality pharma companies. She has significant experience in the US respiratory sector and was, until recently, serving as President and Chief Executive Officer of KNOW Bio, LLC and its wholly owned subsidiary, Novoclem Therapeutics, Inc. Previously, Anne was Executive Vice President and Company Group Chairman at Valeant Pharmaceuticals. Prior to that, Anne served as President and Chief Executive Officer of Synta Pharmaceuticals, now part of Madrigal Pharmaceuticals, Inc. She also served as President, North America Pharmaceuticals at Sanofi, and held several commercial leadership roles at GlaxoSmithKline.

Current external appointments

Anne is currently Director and CEO of Dance Biopharm Holdings Inc. and an Independent Director of Cree, Inc., a NASDAQ traded company and is an independent director of Mallinckrodt plc. She is also a trustee for the University of North Alabama.

Kevin Matthews

Non-Executive Director

Appointment to the Board

Kevin Matthews joined the Vectura Board in April 2019

Experience and expertise

Kevin has more than 20 years’ experience in senior management roles in the chemical, technology and pharmaceutical sectors. He has significant marketing, strategy and management expertise and was, until the end of 2018, Executive Chair of Itaconix plc, an AIM-listed polymers business, having successfully led the organisation as Chief Executive Officer. A Fellow of the Royal Society of Chemistry, Kevin has a strong technical background and has previously held CEO roles at technology companies including Isogenica, a privately-held antibody drug discovery company and Oxonica plc, an advanced materials business. Prior to this he held leadership roles in multinational chemical companies Rhodia S.A, Albright & Wilson plc and ICI. He served as a Non-Executive Director and Remuneration Committee Chair of Elementis plc, a FTSE 250 specialty chemicals business from 2005 to 2014. He also served as a Non-Executive Director of Cellectricon AB, a Swedish biotechnology company dedicated to drug discovery and research in the areas of chronic pain and neurodegenerative disease, from 2011 to 2014.

Current external appointments

Kevin is CEO of the privately held specialty chemicals company, Scott Bader Limited.

John Murphy

General Counsel and Company Secretary

Appointment

John Murphy joined Skyepharma as general counsel in March 2006 and was appointed as General Counsel and Company Secretary of Vectura in June 2016 following the merger.

Experience and expertise

John is a lawyer with extensive experience in legal and company secretarial roles in listed pharmaceutical and biotechnology companies including Medeva PLC, Celltech Group PLC and Pharmagene PLC. He is chairman of the BIA Intellectual Property Advisory Committee and a member of the EuropaBio Intellectual Property Working Group. He holds a BSc in aeronautical engineering from Bristol University and is a qualified solicitor.

Geraldine Venthoye

Executive Vice President – Pharmaceutical Development

Appointment

Dr Geraldine Venthoye joined Vectura in June 2016 upon completion of the merger with Skyepharma PLC, where she had been executive vice president pharmaceutical development since 2013, having joined Skyepharma as head of inhalation business unit in September 2003.

Experience and expertise

Geraldine is a UK registered pharmacist and holds a doctorate degree in pharmaceutics from the University of London.

Geraldine held senior CMC leadership and scientific roles in Inhale/Nektar Therapeutics, San Carlos, California, US, and, prior to this in the UK, held scientific positions in inhalation drug delivery at Vandsons Research and Norton Healthcare.

David Lescuyer

Executive Vice President – Oral Business

Appointment

David Lescuyer joined Vectura in June 2016 upon completion of the merger with Skyepharma PLC, where he had been executive vice president – oral business since April 2016.

Experience and expertise

David, a French national, holds a BSc in mechanical engineering and an MBA from HEC Paris.

David joined Skyepharma from Patheon Pharmaceuticals, where he was executive director and general manager, Patheon France, and more recently global VP, operational excellence. Prior to Patheon, David’s career included experience with Fareva, Cenexi and Catalent in senior operational and general management roles.

Joanne Hombal

Executive Vice President – Human Resources

Appointment

Joanne Hombal joined Vectura in January 2015.

Experience and expertise

Joanne has a BSc in psychology from the University of Birmingham and a postgraduate diploma in human resource management from the University of Glamorgan and is a Chartered Member of the Institute of Personnel and Development.

Before joining Vectura, Joanne was vice president HR at Invensys Rail, with responsibility for setting and leading the people strategy for Northern Europe. She has also held senior HR roles in the financial services and ICT industries and led a number of organisational development and transformation initiatives.

Antony Fitzpatrick

Executive Vice President Operations

Appointment

Antony Fitzpatrick joined Vectura in July 2017.

Experience and expertise

Antony has a first class BSc in aeronautical engineering from the University of Manchester and an MSc in numerical computation from the University of Manchester Institute of Science and Technology.

Antony joined Vectura from Baxter, where he had worked since 1999, having been responsible for global supply chain and most recently VP manufacturing and supply chain for EMEA. This role included operations with 24 manufacturing sites, production values worth over $1.5bn, 9,000 employees and capex of over $100m. His Baxter experience includes operating in both a pharma product environment and in product device and pure medical device operations. Prior to working at Baxter he worked in various manufacturing and logistics roles for Ingram Micro (IT technology), Exel Logistics, Coopers and Lybrand and Mobil Oil.

Christina Olsen

Executive Vice President - Corporate Strategy and Communications

Appointment

Christina Olsen joined Vectura in November 2016 and was appointed to the Executive Leadership Team in August 2019.

Experience and Expertise

Christina graduated from the Stockholm School of Economics with a Master’s in Business and Economics, majoring in Finance and Business Strategy.

Before joining Vectura, Christina spent almost a decade in leadership roles at AstraZeneca, where her responsibilities included strategic insight to shape corporate strategy, as well as product strategy across therapeutic areas. Christina also led a corporate initiative delivering a step change in payer capabilities. Her last role at AstraZeneca was as VP for competitive intelligence and forecasting for the global respiratory, inflammation and autoimmune portfolio.

She also worked for Chiron Corporation for three years, leading business development, and spent nine years at Boston Consulting Group, where she led and managed client projects, including biotech and top ten pharmaceutical company mergers.

Sharon Johnson

Executive Vice President - Delivery Management

Appointment

Sharon Johnson joined Vectura in February 2020.

Experience and Expertise

Sharon holds a postgraduate Diploma in Industrial Pharmaceutical Studies with Distinction from Brighton University and a BS Honours degree in Biological Sciences/Microbiology from North East Surrey College of Technology.

She has more than thirty years of experience in the pharmaceutical industry, and prior to joining Vectura has held a number of executive positions, most recently as Senior Vice President, Global Quality and Regulatory Affairs at Catalent, one of the world’s leading CDMOs.

Earlier in her career, she held the position of Vice President of Quality for GE Healthcare’s Medical Diagnostic Division, and worked in roles of increasing responsibility for Baxter Healthcare and Sanofi Aventis.

Mark Bridgewater

Chief Commercial Officer

Appointment
Mark Bridgewater joined Vectura in March 2020.

Experience and expertise
Mark has more than 20 years of experience in medical device and pharmaceutical services. Prior to joining Vectura he was VP Business Development and Account Management for Europe and Asia at Flex, a global design, engineering and manufacturing organisation. Prior to this, he was VP Global Business Development, Advanced Delivery Technologies at Catalent, and earlier in his career worked as Head of Global Manufacturing Services at Wockhardt and Senior Business Manager, Italy, for Patheon.